Fundación Puigvert, Barcelona Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2008
NCT00634621
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Fundación Puigvert, Barcelona. Spain

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glomerulonephritis, Membranous (Phase 3)

Kidney Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5